Introduction to a review series on the treatment of thrombocytopenic disorders: something old, something new
Francesco Rodeghiero

Thrombocytopenia may be a major component of several disorders, exposing patients to an increased risk of bleeding and/or heralding more complex, but often underestimated, clinical scenarios. In a series of reviews in Haematologica, leading authors comprehensively discuss the management of thrombocytopenia in three distinct clinical areas generally neglected and still lacking specific treatments.1-3 Inherited thrombocytopenias,1 drug-induced immune thrombocytopenia2 and chemotherapy-induced thrombocytopenia3 were chosen as illustrative epitomes. In the review on drug-induced immune thrombocytopenia, three subsections expand beyond classical cases of drug-associated thrombocytopenia to include, in addition to the well-known heparin-induced thrombocytopenia, two rare complications recently reported in association with vaccination against coronavirus disease 2019 (COVID-19) – vaccine-induced thrombotic thrombocytopenia4 and vaccine-associated immune thrombocytopenia.